Tarveda Therapeutics
Kapil Dhingra is an advisor at Tarveda Therapeutics. Kapil has also previously served as the chairman of the board at Exosome Diagnostics, a company which was acquired by Bio-Techne for up to $ 575 million. Dhingra has also been a member of the board of directors at Five Prime Therapeutics, Inc., a company which was acquired by Amgen for $ 1.9 billion.
Kapil Dhingra attended the All India Institute of Medical Sciences, where they earned their Doctor of Medicine (M.D.) degree in medicine.
This person is not in the org chart
This person is not in any offices
Tarveda Therapeutics
Tarveda Therapeutics is a clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin® miniature drug conjugates, for the treatment of patients with various solid tumor malignancies.